Iatrogenic mitochondriopathies: a recent lesson from nucleoside/nucleotide reverse transcriptase inhibitors.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-94-007-2869-1_16PMID 22399431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

  2009cited by this paper
• Origin of pyrimidine deoxyribonucleotide pools in perfused rat heart: implications for 3'-azido-3'-deoxythymidine-dependent cardiotoxicity.

  2009cited by this paper
• Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3.

  2009cited by this paper
• The nephrotoxic effects of HAART

  2009cited by this paper
• Mitochondrial DNA base excision repair and mitochondrial DNA mutation in human hepatic HuH-7 cells exposed to stavudine.

  2009cited by this paper
• R964C Mutation of DNA Polymerase γ Imparts Increased Stavudine Toxicity by Decreasing Nucleoside Analog Discrimination and Impairing Polymerase Activity

  2009cited by this paper
• Mitochondrial DNA Haplogroups Influence Lipoatrophy After Highly Active Antiretroviral Therapy

  2009cited by this paper
• Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.

  2009cited by this paper
• Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis.

  2008cited by this paper
• Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice.

  2008cited by this paper
• Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.

  2008cited by this paper
• Can We Predict Neuropathy Risk before Stavudine Prescription in a Resource-Limited Setting?

  2008cited by this paper
• Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine.

  2008cited by this paper
• Clinical features of adverse reactions associated with telbivudine.

  2008cited by this paper
• Effects of Zidovudine and Stavudine on Mitochondrial DNA of Differentiating 3T3-F442a Cells Are Not Associated with Imbalanced Deoxynucleotide Pools

  2008cited by this paper
• Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors.

  2008cited by this paper
• Renal Transport of Adefovir, Cidofovir, and Tenofovir by SLC22A Family Members (hOAT1, hOAT3, and hOCT2)

  2007cited by this paper
• Phosphorylation of thymidine and AZT in heart mitochondria

  2007cited by this paper
• Exonuclease Removal of Dideoxycytidine (Zalcitabine) by the Human Mitochondrial DNA Polymerase

  2007cited by this paper
• Mitochondrial Toxicity of Tenofovir, Emtricitabine and Abacavir Alone and in Combination with Additional Nucleoside Reverse Transcriptase Inhibitors

  2007cited by this paper
• DNA replication and transcription in mammalian mitochondria.

  2007cited by this paper
• Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition

  2007cited by this paper
• Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment.

  2007cited by this paper
• Direct, DNA pol-γ-independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics

  2007cited by this paper
• Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir

  2007cited by this paper
• Prevalence of and risk factors for HIV‐associated neuropathy in Melbourne, Australia 1993–2006

  2007cited by this paper
• The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity

  2007cited by this paper
• Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia.

  2007cited by this paper
• Comparison of the Phosphorylation of 4′-Ethynyl 2′,3′-Dihydro-3′-Deoxythymidine with That of Other Anti-Human Immunodeficiency Virus Thymidine Analogs

  2007cited by this paper
• Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

  2007cited by this paper
• Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women.

  2007cited by this paper
• Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131

  2007cited by this paper
• Telbivudine: a new treatment for chronic hepatitis B.

  2007cited by this paper
• Expression of deoxynucleoside kinases and 5'-nucleotidases in mouse tissues: implications for mitochondrial toxicity.

  2007cited by this paper
• A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.

  2007cited by this paper
• AIDS Res Hum Retroviruses

  2006cited by this paper
• DNA polymerase gamma in mitochondrial DNA replication and repair.

  2006cited by this paper
• Advances in Understanding Drug-Induced Neuropathies

  2006cited by this paper
• Protection of azidothymidine-induced cardiopathology in mice by mildronate, a mitochondria-targeted drug.

  2006cited by this paper
• Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis.

  2006cited by this paper
• Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients

  2006cited by this paper
• Tissue-Specific Associations Between Mitochondrial DNA Levels and Current Treatment Status in HIV-Infected Individuals

  2006cited by this paper
• Activity profiles of deoxynucleoside kinases and 5'-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs.

  2005cited by this paper
• Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS

  2005cited by this paper
• Functional Characterization of Novel Human and Mouse Equilibrative Nucleoside Transporters (hENT3 and mENT3) Located in Intracellular Membranes*

  2005cited by this paper
• Rhabdomyolysis Due to Lamivudine Administration in a Liver Transplant Recipient

  2005cited by this paper
• Extensive Investigations of Mitochondrial DNA Genome in Treated HIV-Infected Subjects: Beyond Mitochondrial DNA Depletion

  2005cited by this paper
• Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients

  2005cited by this paper
• DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity.

  2005cited by this paper
• Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study

  2005cited by this paper
• Mechanisms of HIV and Nucleoside Reverse Transcriptase Inhibitor Injury to Mitochondria

  2005cited by this paper
• Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy

  2005cited by this paper
• Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.

  2005cited by this paper
• Drug-associated mitochondrial toxicity and its detection.

  2005cited by this paper
• Expression of Deoxynucleotide Carrier Is Not Associated with the Mitochondrial DNA Depletion Caused by Anti-HIV Dideoxynucleoside Analogs and Mitochondrial dNTP Uptake

  2005cited by this paper
• Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage

  2005cited by this paper
• Uridine in the Prevention and Treatment of Nrti-Related Mitochondrial Toxicity

  2005cited by this paper
• Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine

  2004cited by this paper
• Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies.

  2004cited by this paper
• Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs*

  2004cited by this paper
• Activity, Safety, and Immunological Effects of Hydroxyurea Added to Didanosine in Antiretroviral-Naive and Experienced HIV Type 1-Infected Subjects: A Randomized, Placebo-Controlled Trial, ACTG 307

  2004cited by this paper
• Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.

  2004cited by this paper
• Upregulatory Mechanisms Compensate for Mitochondrial DNA Depletion in Asymptomatic Individuals Receiving Stavudine Plus Didanosine

  2004cited by this paper
• The role of thymidine kinases in the activation of pyrimidine nucleoside analogues.

  2004cited by this paper
• Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.

  2004cited by this paper
• Mitochondrial disorders.

  2004cited by this paper
• High Rate of Didanosine-Related Mitochondrial Toxicity in HIV/HCV-Coinfected Patients Receiving Ribavirin

  2004cited by this paper
• Emtricitabine: A Once-Daily Nucleoside Reverse Transcriptase Inhibitor

  2004cited by this paper
• Lack of Recurrence of Hyperlactatemia in HIV-Infected Patients Switched From Stavudine to Abacavir or Zidovudine

  2004cited by this paper
• Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy

  2004cited by this paper
• The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.

  2004cited by this paper
• Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine.

  2004cited by this paper
• Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.

  2004cited by this paper
• Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors.

  2003cited by this paper
• Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy.

  2003cited by this paper
• Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs.

  2003cited by this paper
• Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

  2003cited by this paper
• 3'-azido-3'-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta.

  2003cited by this paper
• Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells

  2003cited by this paper
• Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective

  2003cited by this paper
• Nucleoside analogues and neuropathy in the era of HAART.

  2003cited by this paper
• Lipid Oxidative Markers Are Significantly Increased in Lipoatrophy But Not in Sustained Asymptomatic Hyperlactatemia

  2003cited by this paper
• Mitochondrial deoxyguanosine kinase mutations and mitochondrial DNA depletion syndrome

  2003cited by this paper
• Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.

  2003cited by this paper
• Effect of antioxidants on glucose metabolism and plasma lipids in HIV-infected subjects with lipoatrophy.

  2003cited by this paper
• L-Carnitine Reduces Lymphocyte Apoptosis and Oxidant Stress in HIV-1-Infected Subjects Treated with Zidovudine and Didanosine

  2002cited by this paper
• Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea

  2002cited by this paper
• Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

  2002cited by this paper
• Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*.

  2002cited by this paper
• Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors

  2002cited by this paper
• Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy

  2002cited by this paper
• HIV-1/AIDS and maternal and child health in Africa.

  2002cited by this paper
• Inhibition of phosphate transport in rat heart mitochondria by 3'-azido-3'-deoxythymidine due to stimulation of superoxide anion mitochondrial production.

  2002cited by this paper
• Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors

  2002cited by this paper
• Tenofovir Diphosphate Is a Poor Substrate and a Weak Inhibitor of Rat DNA Polymerases α, δ, and ε*

  2002cited by this paper
• Mildronate: cardioprotective action through carnitine-lowering effect.

  2002cited by this paper
• Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

  2002cited by this paper
• Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence?

  2002cited by this paper
• Exposure to Dideoxynucleosides Is Reflected in Lowered Mitochondrial DNA in Subcutaneous Fat

  2002cited by this paper
• The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals

  2001cited by this paper

• Small molecules in the treatment of COVID-19

  2022cites this paper
• Mutational Analysis and mtDNA Haplogroup Characterization in Three Serbian Cases of Mitochondrial Encephalomyopathies and Literature Review

  2021cites this paper
• Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study

  2020cites this paper
• High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial

  2018cites this paper
• Azidothymidine-triphosphate impairs mitochondrial dynamics by disrupting the quality control system

  2017cites this paper
• Dolutegravir Monotherapy as Treatment De-Escalation in HIV-Infected Adults with Virological Control: DoluMono Cohort Results

  2016cites this paper
• Implications of Pharmacogenetics for Antimicrobial Prescribing

  2016cites this paper
• Pharmacogenomics of antimicrobial agents.

  2014cites this paper
• Mitotoxicity in distal symmetrical sensory peripheral neuropathies

  2014cites this paper
• Animal models of peripheral neuropathy: modeling what we feel, understanding what they feel.

  2014cites this paper
• Target-Organ Toxicity: Liver and Kidney

  2014cites this paper
• Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain.

  2014cites this paper
• HIV-1 Vpr enhances PPARβ/δ-mediated transcription, increases PDK4 expression, and reduces PDC activity.

  2013cites this paper
• Metabolic pathways as regulators of HIV infection

  2013cites this paper
• Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology

  2013cites this paper
• Therapy-related hepatic mitochondrial dysfunction in patients co-infected with human immunodeficiency virus and hepatitis C virus and in HepG2 cells

  2012cites this paper